Journal
CELL HOST & MICROBE
Volume 29, Issue 4, Pages 516-+Publisher
CELL PRESS
DOI: 10.1016/j.chom.2021.03.009
Keywords
-
Categories
Funding
- National Institute of Allergy and Infectious Diseases (NIAID), the National Institutes of Health (NIH) [P51 OD011132, 3U19AI05726617S1, U19AI090023, R01AI127799, R01AI148378, K99AI153736, 1UM1AI148576-01, 5R38AI140299-03, UM1AI148684]
- Oliver S. and Jennie R. Donaldson Charitable Trust
- Emory Executive Vice President for Health Affairs Synergy Fund award
- Pediatric Research Alliance Center for Childhood Infections and Vaccines and Children's Healthcare of Atlanta
- Woodruff Health Sciences Center
- Emory School of Medicine
- Woodruff Health Sciences Center 2020 COVID-19 CURE Award
- Vital Projects/Proteus funds
Ask authors/readers for more resources
Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.
The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies. We compared antibody binding and live virus neutralization of sera from naturally infected and Moderna-vaccinated individuals against two SARS-CoV-2 variants: B.1 containing the spike mutation D614G and the emerging B.1.351 variant containing additional spike mutations and deletions. Sera from acutely infected and convalescent COVID-19 patients exhibited a 3-fold reduction in binding antibody titers to the B.1.351 variant receptor-binding domain of the spike protein and a 3.5-fold reduction in neutralizing antibody titers against SARS-CoV-2 B.1.351 variant compared to the B.1 variant. Similar results were seen with sera from Moderna-vaccinated individuals. Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available